Evidence map›Paper›PMID 40608058›Full record

ArticleeLife2025

C-C chemokine receptor 4 deficiency exacerbates early atherosclerosis in mice.

Toru Tanaka, Naoto Sasaki, Aga Krisnanda, Hilman Zulkifli Amin, Ken Ito, Sayo Horibe, Kazuhiko Matsuo, Ken-Ichi Hirata, Takashi Nakayama, Yoshiyuki Rikitake

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Toru Tanaka *Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.ORCID https://orcid.org/0000-0002-1054-9211
Naoto Sasaki *Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.ORCID https://orcid.org/0000-0002-7760-6129
Aga KrisnandaLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.ORCID https://orcid.org/0009-0005-6417-2738
Hilman Zulkifli AminLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
Ken ItoLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
Sayo HoribeLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.ORCID https://orcid.org/0000-0002-4111-2426
Kazuhiko MatsuoDivision of Chemotherapy, Faculty of Pharmacy, Kindai University, Higashi-osaka, Japan.ORCID https://orcid.org/0000-0001-5782-5300
Ken-Ichi HirataDivision of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Takashi NakayamaDivision of Chemotherapy, Faculty of Pharmacy, Kindai University, Higashi-osaka, Japan.ORCID https://orcid.org/0000-0002-8493-899X
Yoshiyuki RikitakeLaboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.ORCID https://orcid.org/0000-0001-7207-4656

Funding

KAKENHI JP21K08042KAKENHI JP24K11301
6 · The paper itself

Abstract

Chronic inflammation via dysregulation of T cell immune responses is critically involved in the pathogenesis of atherosclerotic cardiovascular disease. Improving the balance between proinflammatory T cells and anti-inflammatory regulatory T cells (Tregs) may be an attractive approach for treating atherosclerosis. Although C-C chemokine receptor 4 (CCR4) has been shown to mediate the recruitment of T cells to inflamed tissues, its role in atherosclerosis is unclear. Here, we show that genetic deletion of CCR4 in hypercholesterolemic mice accelerates the development of early atherosclerotic lesions characterized by an inflammatory plaque phenotype. This was associated with the augmentation of proinflammatory T helper type 1 (Th1) cell responses in peripheral lymphoid tissues, para-aortic lymph nodes, and atherosclerotic aorta. Mechanistically, CCR4 deficiency in Tregs impaired their suppressive function and tended to inhibit their migration to the atherosclerotic aorta, and subsequently augmented Th1 cell-mediated immune responses through defective regulation of dendritic cell function, which accelerated aortic inflammation and atherosclerotic lesion development. Thus, we revealed a previously unrecognized role for CCR4 in controlling the early stage of atherosclerosis via Treg-dependent regulation of proinflammatory T cell responses. Our data suggest that CCR4 is an important negative regulator of atherosclerosis.

Indexed as

AtherosclerosisReceptors, CCR4AnimalsAortaDendritic CellsDisease Models, AnimalMiceMice, Inbred C57BLMice, KnockoutTh1 CellsT-Lymphocytes, RegulatoryCcr4 protein, mouseReceptors, CCR4atherosclerosischemokine receptorimmunologyinflammationmedicinemouseT cell

Identifiers

PMID40608058
PMCPMC12226018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.